Lymphoblastic Leukemia, Acute
Conditions
Keywords
Ph+ Acute Lymphoblastic Leukaemia, Dasatinib, targeted therapy, Patients with Ph positive and or BCR ABL positive ALL
Brief summary
The primary objective of the trial is to estimate the activity of BMS-354825 (Dasatinib) in de novo adult Ph+ ALL patients in terms of hematological complete remission (HCR) rate.
Detailed description
This open label phase II study of Dasatinib will enroll adult de novo Ph+ ALL patients. A minimum of 48 cases will be required to complete the study. Accrual is expected to be completed in 18 months. The study will be considered completed for patients in HCR after completion of a total of 12 weeks of treatment. After completion patients will go off study and will be treated according to the best treatment option for Ph+ ALL patients in 1st HCR. The enrollment in the post-remissional phase of the current GIMEMA LAL protocol will be suggested.
Interventions
DRUGDasatinib
Sponsors
Gruppo Italiano Malattie EMatologiche dell'Adulto
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with Ph+ and/or BCR/ABL+ ALL * Age ≥18 years old * De novo ALL (within 14 days from diagnosis) * No prior treatment with any anti-leukemic drugs with the exception of steroids for no more than 14 days (including the 7-day pretreatment already scheduled in the protocol) * WHO performance status ≤2 * Absence of central nervous system (CNS) leukemia * Normal serum level of potassium, total calcium corrected for serum albumin magnesium and phosphorus, or correctable with supplements * ALT and AST ≤2.5 x ULN or ≤5.0 x ULN if considered due to leukemia * Alkaline phosphatase ≤2.5 x ULN unless considered to leukemia * Serum bilirubin ≤2 x ULN * Serum creatinine ≤3 x ULN * Serum amylase ≤1.5 x ULN and serum lipase ≤1.5 x ULN * Normal cardiac function * Written informed consent prior to any study procedures being performed.
Exclusion criteria
* Impaired cardiac function, including any one of the following: * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BMS-354825 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection) * Use of therapeutic warfarin * Acute or chronic liver or renal disease considered unrelated to leukemia * Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol * Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM¬CSF) ≤1 week prior to starting study drug * Patients who are currently receiving treatment with any of the medications listed in Appendix F and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in Appendix F have the potential to prolong the QT interval. * Patients who have received any anti-leukemic agents and treatments including steroids for more than 14 days including 7 days pretreatment that is part of the protocol * Patients who have received any investigational drug in the last 2 weeks * Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who have not recovered from side effects of such therapy * Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of BMS-354825). Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug * Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory) * Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention * Non compliant to oral medication patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of Hematological Complete Remission (HCR) Obtained During the BMS Induction Treatment Within Day +85 From the Start of BMS (i.e., Whenever Achieved From the Start of the Experimental Drug). | End of the study, up to day 85 |
Secondary
| Measure | Time frame |
|---|---|
| The Best Cytogenetic Response Obtained During BMS Treatment Within Day +85, Whenever Achieved From the Start of the Experimental Drug; | End of study |
| the Best Molecular Response Obtained During BMS Treatment Within Day +85, Whenever Achieved From the Start of the Experimental Drug; | End of study |
| The Incidence of Grade >2 CTC-NCI Side Effects and Toxicities; | End of study |
| the Cumulative Incidence of Relapse; | End of study |
| OS, Defined as the Time Interval Between Inclusion and Death for Any Cause. | End of study |
| DFS, Defined as the Time Interval Between the Evaluation of HCR and Hematological Relapse of the Disease or Death in First HCR; | End of study |
Countries
Italy
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dasatinib All patients registered in the study. | 53 |
| Total | 53 |
Baseline characteristics
| Characteristic | Dasatinib |
|---|---|
| Age, Continuous | 53.61 Years |
| Gender Female | 27 Participants |
| Gender Male | 26 Participants |
| White Blood Cells | 18.80 *10^9 cells/L |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 12 / 53 |
| serious Total, serious adverse events | 13 / 53 |
Outcome results
Primary
Rate of Hematological Complete Remission (HCR) Obtained During the BMS Induction Treatment Within Day +85 From the Start of BMS (i.e., Whenever Achieved From the Start of the Experimental Drug).
Time frame: End of the study, up to day 85
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Study Group | Rate of Hematological Complete Remission (HCR) Obtained During the BMS Induction Treatment Within Day +85 From the Start of BMS (i.e., Whenever Achieved From the Start of the Experimental Drug). | 53 Patients |
Secondary
DFS, Defined as the Time Interval Between the Evaluation of HCR and Hematological Relapse of the Disease or Death in First HCR;
Time frame: End of study
Secondary
OS, Defined as the Time Interval Between Inclusion and Death for Any Cause.
Time frame: End of study
Secondary
The Best Cytogenetic Response Obtained During BMS Treatment Within Day +85, Whenever Achieved From the Start of the Experimental Drug;
Time frame: End of study
Secondary
the Best Molecular Response Obtained During BMS Treatment Within Day +85, Whenever Achieved From the Start of the Experimental Drug;
Time frame: End of study
Secondary
the Cumulative Incidence of Relapse;
Time frame: End of study
Secondary
The Incidence of Grade >2 CTC-NCI Side Effects and Toxicities;
Time frame: End of study